Imagine your liver biopsy being scored not by a panel of pathologists, but by an AI that regulators officially treat as…

Imagine your liver biopsy being scored not by a panel of pathologists, but by an AI that regulators officially treat as a “lab tool” for drug trials. That just became real.

PathAI has announced that its AIM-MASH AI Assist system is the first AI-powered pathology tool ever qualified by the US FDA (and already by the European Medicines Agency) for use in clinical trials of MASH — a common, fatty liver disease that can progress to cirrhosis and cancer. Instead of three experts arguing over how bad the damage looks on a slide, the model helps a single pathologist assign consistent scores.

Why this matters: drug trials for liver disease live and die on tiny changes in biopsy scores. Human reads are slow, expensive and notoriously variable. An AI that gives the same answer every time for the same slide can make trials faster, cheaper and statistically cleaner — which may mean more liver drugs actually making it to market.

Important caveat: this AI is cleared only as a biomarker tool for trials, not for diagnosing individual patients. But if regulators are starting to trust models as part of the evidence pipeline, how long until similar systems sit inside routine hospital workflows?

Would you be comfortable knowing an AI scored your tissue sample in a drug trial? Should this kind of model stay in research, or gradually move into everyday diagnostics?

Full story from PathAI’s press release: https://www.pathai.com/news/pathais-aim-mash-ai-assist-becomes-first-ai-powered-pathology-tool-to-receive-fda-qualification-for-mash-clinical-trials

#AI #medicine #pathology #liverdisease #clinicaltrials #FDA #biotech